Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BHST NASDAQ:CNTX NASDAQ:FLNA NASDAQ:QCLS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBHSTBioHarvest Sciences$2.85+2.1%$3.38$2.70▼$12.80$55.90M0.8729,341 shs46,992 shsCNTXContext Therapeutics$0.62-0.3%$1.53$0.55▼$3.62$57.06M1.751.85 million shs896,847 shsFLNACassava Sciences$1.11+1.7%$1.28$1.07▼$4.98$53.58M-0.73524,868 shs123,880 shsQCLSMymd Pharmaceuticals$3.45$3.90$2.50▼$17.39$14.39M2.12750,877 shs121,448 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBHSTBioHarvest Sciences+0.72%-3.79%-12.81%-35.12%-60.43%CNTXContext Therapeutics-0.14%-11.01%-55.19%-75.18%-14.93%FLNACassava Sciences-5.22%-16.79%-12.80%-31.45%-49.54%QCLSMymd Pharmaceuticals+0.58%-5.99%-10.85%+344,999,900.00%+344,999,900.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBHSTBioHarvest Sciences$2.85+2.1%$3.38$2.70▼$12.80$55.90M0.8729,341 shs46,992 shsCNTXContext Therapeutics$0.62-0.3%$1.53$0.55▼$3.62$57.06M1.751.85 million shs896,847 shsFLNACassava Sciences$1.11+1.7%$1.28$1.07▼$4.98$53.58M-0.73524,868 shs123,880 shsQCLSMymd Pharmaceuticals$3.45$3.90$2.50▼$17.39$14.39M2.12750,877 shs121,448 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBHSTBioHarvest Sciences+0.72%-3.79%-12.81%-35.12%-60.43%CNTXContext Therapeutics-0.14%-11.01%-55.19%-75.18%-14.93%FLNACassava Sciences-5.22%-16.79%-12.80%-31.45%-49.54%QCLSMymd Pharmaceuticals+0.58%-5.99%-10.85%+344,999,900.00%+344,999,900.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBHSTBioHarvest Sciences 2.00Hold$10.00251.00% UpsideCNTXContext Therapeutics 2.89Moderate Buy$6.17893.02% UpsideFLNACassava Sciences 2.00Hold$5.00350.86% UpsideQCLSMymd Pharmaceuticals 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest QCLS, FLNA, BHST, and CNTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/18/2026BHSTBioHarvest Sciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/16/2026CNTXContext Therapeutics Maxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$8.00 ➝ $4.006/3/2026BHSTBioHarvest Sciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/26/2026FLNACassava Sciences Maxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$5.005/13/2026QCLSMymd Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageSell (E+)4/22/2026FLNACassava Sciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/20/2026CNTXContext Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 7/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBHSTBioHarvest Sciences$34.51M1.62N/AN/A$1.30 per share2.19CNTXContext TherapeuticsN/AN/AN/AN/A$0.66 per shareN/AFLNACassava SciencesN/AN/AN/AN/A$1.54 per shareN/AQCLSMymd PharmaceuticalsN/AN/AN/AN/A$5.19 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBHSTBioHarvest Sciences-$11.14M-$0.59N/AN/AN/A-32.54%-76.03%-25.30%8/10/2026 (Estimated)CNTXContext Therapeutics-$36.12M-$0.42N/AN/AN/AN/A-59.95%-54.78%8/5/2026 (Estimated)FLNACassava Sciences-$90.97M-$1.61N/AN/AN/AN/A-53.90%-34.20%N/AQCLSMymd Pharmaceuticals-$11.63M-$20.69N/AN/AN/AN/A-76.40%-35.10%N/ALatest QCLS, FLNA, BHST, and CNTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/10/2026Q2 2026BHSTBioHarvest Sciences-$0.13N/AN/AN/A$9.45 millionN/A8/5/2026Q2 2026CNTXContext Therapeutics-$0.10N/AN/AN/AN/AN/A5/15/2026Q1 2026QCLSMymd PharmaceuticalsN/A-$0.19N/A-$0.19N/AN/A5/14/2026Q1 2026BHSTBioHarvest Sciences-$0.13-$0.11+$0.02-$0.11$8.50 million$8.51 million5/7/2026Q1 2026FLNACassava SciencesN/A-$0.21N/A-$0.21N/AN/A5/6/2026Q1 2026CNTXContext Therapeutics-$0.12-$0.09+$0.03-$0.09N/AN/A4/15/2026Q4 2025QCLSMymd PharmaceuticalsN/A$6.11N/A$6.11N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBHSTBioHarvest SciencesN/AN/AN/AN/AN/ACNTXContext TherapeuticsN/AN/AN/AN/AN/AFLNACassava SciencesN/AN/AN/AN/AN/AQCLSMymd PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBHSTBioHarvest Sciences0.032.962.44CNTXContext TherapeuticsN/A8.968.96FLNACassava SciencesN/A2.192.19QCLSMymd PharmaceuticalsN/A3.723.72Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBHSTBioHarvest SciencesN/ACNTXContext Therapeutics14.03%FLNACassava Sciences38.05%QCLSMymd Pharmaceuticals9.64%Insider OwnershipCompanyInsider OwnershipBHSTBioHarvest SciencesN/ACNTXContext Therapeutics4.80%FLNACassava Sciences4.60%QCLSMymd Pharmaceuticals0.86%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBHSTBioHarvest SciencesN/A19.62 millionN/AN/ACNTXContext Therapeutics791.88 million87.47 millionNot OptionableFLNACassava Sciences2048.31 million46.09 millionOptionableQCLSMymd Pharmaceuticals64.17 million4.13 millionN/AQCLS, FLNA, BHST, and CNTX HeadlinesRecent News About These CompaniesQ/C Technologies Relocates Headquarters to San Francisco in Proximity to World-Class Engineering Experts for Photonic Computing and Optical AI Inference InitiativeJuly 1, 2026 | globenewswire.comQ/C Technologies Relocates Headquarters to San Francisco in Proximity to World-Class Engineering Experts for Photonic Computing and Optical AI Inference InitiativeJune 30, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeQCLS, FLNA, BHST, and CNTX Company DescriptionsBioHarvest Sciences NASDAQ:BHST$2.85 +0.06 (+2.11%) As of 02:18 PM Eastern This is a fair market value price provided by Massive. Learn more.BioHarvest Sciences Inc. is a biotech firm. It focused on leveraging its botanical synthesis technology to develop science-based and clinically proven therapeutic solutions, within business verticals nutraceutical health and wellness products such as dietary supplements and development of plant cell-based Active Pharmaceutical Ingredients which focus on specific medical indications. BioHarvest Sciences Inc. is based in Vancouver, Canada.Context Therapeutics NASDAQ:CNTX$0.62 0.00 (-0.31%) As of 02:23 PM Eastern This is a fair market value price provided by Massive. Learn more.Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.Cassava Sciences NASDAQ:FLNA$1.11 +0.02 (+1.74%) As of 02:00 PM EasternFilana Therapeutics Inc is a biotechnology company focused on developing novel, investigational therapies to modulate the filamin A protein for the treatment of central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and other diseases associated with dysregulation or overexpression of filamin A. Its therapeutic product candidate, simufilam, is a proprietary small molecule oral treatment drug being studied for the treatment of TSC-related epilepsy.Mymd Pharmaceuticals NASDAQ:QCLS$3.45 0.00 (0.00%) As of 02:22 PM Eastern This is a fair market value price provided by Massive. Learn more.TNF Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms. Its MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. The MYMD-1 is being developed to treat diseases and disorders marked by acute or chronic inflammation. The company's second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy. The Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve the growing CBD market, which includes FDA approved drugs and CBD products not regulated as drugs. TNF Pharmaceuticals, Inc. was formerly known as MyMD Pharmaceuticals, Inc. and changed its name to TNF Pharmaceuticals, Inc. in July 2024. The company was founded in 2014 and is headquartered in Baltimore, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Alphabet’s AI Spending Question Looms Over Q2 Earnings 3 Small-Cap Stocks Trading Under $10 With Room to Run Plot Twist: 12 States Could Stall the Paramount-Warner Bros. Discovery Mega-Merger 3 Gold Stocks Under $5 With Massive Upside CleanSpark Inks a $6.6B AI Lease to Become a Digital Landlord Tower Semiconductor’s AI Rally Is Built on a Light-Speed Bet Blueprint for a Billion: Nebius Group Secures the AI Floor Marriott vs. Viking: Why the Better Quarter Doesn't Mean the Better Decade Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
